RMD Quote, Financials, Valuation and Earnings

Bio-Rad Laboratories has a net margin of 26.88% compared to ResMed's net margin of -107.24%. ResMed's return on equity of 25.56% beat Bio-Rad Laboratories's return on equity of -23.87%.

ResMed has a consensus price target of $265.42, signalling upside risk potential of 23.98%. On the other hand Bio-Rad Laboratories has an analysts' consensus of $353.17 which suggests that it could grow by 44.16%. Given that Bio-Rad Laboratories has higher upside potential than ResMed, analysts believe Bio-Rad Laboratories is more attractive than ResMed.

ResMed has a beta of 0.755, which suggesting that the stock is 24.514% less volatile than S&P 500. In comparison Bio-Rad Laboratories has a beta of 1.119, suggesting its more volatile than the S&P 500 by 11.924%.

ResMed has a quarterly dividend of $0.53 per share corresponding to a yield of 0.97%. Bio-Rad Laboratories offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed pays 27.65% of its earnings as a dividend. Bio-Rad Laboratories pays out -- of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.3B, which are larger than Bio-Rad Laboratories quarterly revenues of $667.5M. ResMed's net income of $344.6M is higher than Bio-Rad Laboratories's net income of -$715.8M. Notably, ResMed's price-to-earnings ratio is 25.28x while Bio-Rad Laboratories's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 6.41x versus 2.69x for Bio-Rad Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of 26.88% compared to ResMed's net margin of 12.41%. ResMed's return on equity of 25.56% beat Boston Scientific's return on equity of 8.96%.

ResMed has a consensus price target of $265.42, signalling upside risk potential of 23.98%. On the other hand Boston Scientific has an analysts' consensus of $114.78 which suggests that it could grow by 20.75%. Given that ResMed has higher upside potential than Boston Scientific, analysts believe ResMed is more attractive than Boston Scientific.

ResMed has a beta of 0.755, which suggesting that the stock is 24.514% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.

ResMed has a quarterly dividend of $0.53 per share corresponding to a yield of 0.97%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed pays 27.65% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.3B, which are smaller than Boston Scientific quarterly revenues of $4.6B. ResMed's net income of $344.6M is lower than Boston Scientific's net income of $566M. Notably, ResMed's price-to-earnings ratio is 25.28x while Boston Scientific's PE ratio is 76.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 6.41x versus 8.43x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 26.88% compared to ResMed's net margin of -58.2%. ResMed's return on equity of 25.56% beat Masimo's return on equity of -23.05%.

ResMed has a consensus price target of $265.42, signalling upside risk potential of 23.98%. On the other hand Masimo has an analysts' consensus of $195.70 which suggests that it could grow by 28.69%. Given that Masimo has higher upside potential than ResMed, analysts believe Masimo is more attractive than ResMed.

ResMed has a beta of 0.755, which suggesting that the stock is 24.514% less volatile than S&P 500. In comparison Masimo has a beta of 1.278, suggesting its more volatile than the S&P 500 by 27.807%.

ResMed has a quarterly dividend of $0.53 per share corresponding to a yield of 0.97%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed pays 27.65% of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.3B, which are larger than Masimo quarterly revenues of $600.7M. ResMed's net income of $344.6M is higher than Masimo's net income of -$349.6M. Notably, ResMed's price-to-earnings ratio is 25.28x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 6.41x versus 3.93x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 26.88% compared to ResMed's net margin of 8.48%. ResMed's return on equity of 25.56% beat Stryker's return on equity of 15.22%.

ResMed has a consensus price target of $265.42, signalling upside risk potential of 23.98%. On the other hand Stryker has an analysts' consensus of $421.86 which suggests that it could grow by 21.18%. Given that ResMed has higher upside potential than Stryker, analysts believe ResMed is more attractive than Stryker.

ResMed has a beta of 0.755, which suggesting that the stock is 24.514% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.107%.

ResMed has a quarterly dividend of $0.53 per share corresponding to a yield of 0.97%. Stryker offers a yield of 0.94% to investors and pays a quarterly dividend of $0.84 per share. ResMed pays 27.65% of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.3B, which are smaller than Stryker quarterly revenues of $6.4B. ResMed's net income of $344.6M is lower than Stryker's net income of $546M. Notably, ResMed's price-to-earnings ratio is 25.28x while Stryker's PE ratio is 44.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 6.41x versus 5.94x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.